Skip to main content
Log in

Estrogen and estrogen–progestin replacement therapy and risk of postmenopausal breast cancer in Canada

  • Published:
Cancer Causes & Control Aims and scope Submit manuscript

Abstract

Objective: To examine the association between hormone replacement therapy (HRT) use and breast cancer incidence and to determine whether the association differs according to type of regimen. Method: Data were collected in Ontario from 404 incident cases and 403 age frequency-matched controls, between 1995 and 1996, using a self-administered questionnaire. Results: Multivariate analyses revealed an elevated odds ratio among long-term (≥ten years) HRT users (odds ratio (OR) = 1.80, 95% confidence interval (CI) 1.06–3.06). Risk among long-term estrogen–progestin users was substantially higher (OR = 3.48, 95% CI 1.00–12.11) than risk among long-term users of estrogen alone (OR = 1.74, 95% CI 0.93–3.24). Among both estrogen and estrogen–progestin users, positive associations were not observed for durations of use less than ten years. Conclusion: These data suggest that long-term use of HRT increases the risk of breast cancer and that estrogen–progestin therapy may be more detrimental than estrogen use alone.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Barrett-Connor E, Stuenkel CA (2001) Hormone replacement therapy (HRT)-risks and benefits. Int J Epidemiol 30: 423-426.

    Google Scholar 

  2. Writing Group for the PEPI Trial (1996) Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 276: 1389-1396.

    Google Scholar 

  3. Barrett-Connor E, Grady D (1998) Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health 19: 55-72.

    Google Scholar 

  4. Waring SC, Rocca WA, Petersen RC, O'Brien PC, Tangalos EG, Kokmen E (1999) Postmenopausal estrogen replacement therapy and risk of Alzheimer's disease: a population-based study. Neurology 52: 965-970.

    Google Scholar 

  5. Grodstein F, Newcomb PA, Stampfer MJ (1999) Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med 106: 574-582.

    Google Scholar 

  6. Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108411 women without breast cancer. Lancet 350: 1047-1059.

    Google Scholar 

  7. Ross RK, Paganini-Hill A, Wan PC, Pike MC (2000) Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl cancer Inst 92: 328-332.

    Google Scholar 

  8. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R (2000) Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 283: 485-491.

    Google Scholar 

  9. Gapstur SM, Morrow M, Sellers TA (1999) Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa Women's Health Study. JAMA 281: 2091-2097.

    Google Scholar 

  10. Magnusson C, Baron JA, Correia N, Bergstrom R, Adami HO, Persson I (1999) Breast-cancer risk following long-term oestrogenand oestrogen-progestin-replacement therapy. Int J Cancer 81: 339-344.

    Google Scholar 

  11. Anderson E, Clarke RB, Howell A (1998) Estrogen responsiveness and control of normal human breast proliferation. J Mammary Gland Biol Neoplasia 3: 23-35.

    Google Scholar 

  12. Pike MC, Spicer DV, Dahmoush L, Press MF (1993) Estrogens, progestrogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 15: 17-35.

    Google Scholar 

  13. Lacroix AZ, Burke W (1997) Breast cancer and hormone replacement therapy. Lancet 350: 1042-1043.

    Google Scholar 

  14. Hofseth LJ, Raafat AM, Osuch JR, Pathak DR, Slomski CA, Haslam SZ (1999) Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab 84: 4559-4565.

    Google Scholar 

  15. Wysowski DK, Golden L, Burke L (1995) Use of menopausal estrogens and medroxyprogesterone in the United States, 1982-1992. Obstet Gynecol 85: 6-10.

    Google Scholar 

  16. Smith DC, Prentice R, Thompson DJ, Herrmann WL (1975) Association of exogenous estrogen and endometrial carcinoma. N Engl J Med 293: 1164-1167.

    Google Scholar 

  17. Ziel HK, Hinkle WD (1975) Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med 293: 1167-1170.

    Google Scholar 

  18. Persson I, Weiderpass E, Bergkvist L, Bergstrom R, Schairer C (1999) Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement. Cancer Causes Control 10: 253-260.

    Google Scholar 

  19. Percy C, Van Holten V (1990) International Classification of Diseases for Oncology, 2nd edn. Geneva: World Health Organization.

    Google Scholar 

  20. Slupik RI, Allison KC (1997) American Medical Association Complete Guide to Women's Health.

  21. Colditz GA, Hankinson SE, Hunter DJ, et al. (1995) The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 332: 1589-1593.

    Google Scholar 

  22. Persson I, Thurfjell E, Bergstrom R, Holmberg L (1997) Hormone replacement therapy and the risk of breast cancer. Nested case-control study in a cohort of Swedish women attending mammography screening. Int J Cancer 72: 758-761.

    Google Scholar 

  23. Magnusson C, Baron JA, Correia N, Bergstrom R, Adami HO, Persson I (1999) Breast-cancer risk following long-term oestrogenand oestrogen-progestin-replacement therapy. Int J Cancer 81: 339-344.

    Google Scholar 

  24. Colditz GA, Stampfer MJ, Willett WC, et al. (1992) Type of postmenopausal hormone use and risk of breast cancer: 12-year follow-up from the Nurses' Health Study. Cancer Causes Control 3: 433-439.

    Google Scholar 

  25. Colditz GA, Rosner B for the Nurses' Health Study Research Group (1998) Use of estrogen plus progestin is associated with greater increase in breast cancer risk than estrogen alone. Am J Epidemiol 147(Suppl): 64S. Estrogen and estrogen-progestin replacement and breast cancer 589

    Google Scholar 

  26. Palmer JR, Rosenberg L, Clarke EA, Miller DR, Shapiro S (1991) Breast cancer risk after estrogen replacement therapy: results from the Toronto Breast Cancer Study. Am J Epidemiol 134: 1386-1395.

    Google Scholar 

  27. Newcomb PA, Titus-Ernstoff L, Egan KM, et al. (2000) Estrogenprogestin use in relation to risk of lobular and ductal breast cancer. (1998). Am J Epidemiol 151: S64 (abstract).

    Google Scholar 

  28. Pike MC, Ross RK, Spicer DV (1998) Problems involved in including women with simple hysterectomy in epidemiologic studies measuring the effects of hormone replacement therapy on breast cancer risk. Am J Epidemiol 147: 718-721.

    Google Scholar 

  29. Siddle N, Sarrel P, Whitehead M (1987) The effect of hysterectomy on the age at ovarian failure: identification of a subgroup of women with premature loss of ovarian function and literature review. Fertil Steril 51: 604-608.

    Google Scholar 

  30. Kreiger N, Sloan M, Cotterchio M, Kirsh V (1999) The risk of breast cancer following reproductive surgery. Eur J Cancer 35: 97-101.

    Google Scholar 

  31. Laya MB, Larson EB, Taplin SH, White E (1996) Effect of estrogen replacement therapy on the specificity and sensitivity of screening mammography. J Natl Cancer Inst 88: 643-649.

    Google Scholar 

  32. Boyd NF, Lockwood GA, Byng JW, Tritchler DL, Yaffe MJ (1998) Mammographic densities and breast cancer risk. Cancer Epidemiol Biomarkers Prev 7: 1133-1144.

    Google Scholar 

  33. Cauley JA, Lucas FL, Kuller LH, Bogt MT, Browner WS, Cummings SR for the Osteoporotic Fractures Research Group (1996) Bone mineral density and risk of breast cancer in older women. JAMA 276: 611-617.

    Google Scholar 

  34. Erlik Y, Meldrum DR, Judd HL (1982) Estrogen levels in postmenopausal women with hot flashes. Obstet Gynecol 59: 403-407.

    Google Scholar 

  35. Longcope C, Crawford S, McKinlay S (1996) Endogenous estrogens: relationship between estrone, estradiol, non-protein bound estradiol, and hot flashes and lipids. Menopause 3: 77-84.

    Google Scholar 

  36. Johannes CB, Crawford SL, Posner JG, McKinlay SM (1994) Longitudinal patterns and correlates of hormone replacement therapy use in middle-aged women. Am J Epidemiol 140: 439-452.

    Google Scholar 

  37. Bauer DC, Browner WS, Cauley JA, et al. (1993) Factors associated with appendicular bone mass in older women. The Study of Osteoporotic Fractures Research Group. Ann Intern Med 118: 657-665.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kirsh, V., Kreiger, N. Estrogen and estrogen–progestin replacement therapy and risk of postmenopausal breast cancer in Canada. Cancer Causes Control 13, 583–590 (2002). https://doi.org/10.1023/A:1016330024268

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1016330024268

Navigation